Categories
Change Password!
Reset Password!
This triple-blind, placebo-controlled, randomized clinical trial examined the combined analgesic effect of preemptively administering 400 mg of Ibuprofen (IBU) and 2% Potassium fluoride (KF2) separately or together on tooth sensitivity following tooth bleaching.
Preemptive use of 400 mg Ibuprofen plus 2% Potassium fluoride (desensitizer) remarkably decreases tooth sensitivity following in-office bleaching treatments.
This triple-blind, placebo-controlled, randomized clinical trial examined the combined analgesic effect of preemptively administering 400 mg of Ibuprofen (IBU) and 2% Potassium fluoride (KF2) separately or together on tooth sensitivity following tooth bleaching.
Overall 15 participants were included. The study employed a crossover drug administration design and a split-mouth design for the desensitizer agent. Four paired groups were established: IBU plus KF2 (IBU + KF2); IBU alone (IBU + placebo KF); KF2 alone (placebo IBU + KF2); and placebo (placebo IBU + placebo KF).
At baseline (immediately after bleaching), and at 6, 30, and 54 hours post-treatment, tooth sensitivity was examined utilizing a visual analog scale (VAS). Utilizing the Friedman test and relative risk, statistical analysis was done.
When compared to the placebo group, IBU + KF2 illustrated greater efficacy in minimizing tooth sensitivity immediately after bleaching (P < .05). In the placebo arm, the chance of encountering tooth sensitivity (moderate or severe) was four times more as opposed to the IBU + KF2 arm (relative risk, 4.00; 95% Confidence Interval [CI], 1.01 to 15.81; P = .025).
The concurrent utilization of 400 mg of IBU alongside KF2 showed potential in effectively addressing post-bleaching tooth sensitivity. This approach outperformed placebo in yielding enhanced analgesic effects.
The Journal of the American Dental Association
Preemptive use of ibuprofen and desensitizer decreases immediate tooth sensitivity after in-office bleaching: A triple-blind, randomized, placebo-controlled clinical trial
Nathália Larissa Bezerra Lima et al.
Comments (0)